Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies

Ziemssen, T., Neuhaus, O., Farina, C., Hartung, H. P., & Hohlfeld, R. (2002). Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies. Nervenarzt, 73(4), 321-331. doi:10.1007/s00115-001-1257-0.

Item is

Basisdaten

einblenden: ausblenden:
Genre: Zeitschriftenartikel

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Ziemssen, T.1, Autor           
Neuhaus, Oliver2, Autor           
Farina, C.1, Autor           
Hartung, H. P., Autor
Hohlfeld, R.1, Autor           
Affiliations:
1Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society, ou_1113547              
2Karl-Franzens-Universität, Graz, Austria, ou_persistent22              

Inhalt

einblenden:
ausblenden:
Schlagwörter: multiple sclerosis; glatiramer acetate; immunomodulatory therapy
 Zusammenfassung: Glatiramer acetate (GA, Copaxone((R))), a standardized mixture of synthetic polypeptides, has now been approved also in Germany for the treatment of relapsing-remitting multiple sclerosis (RR-MS). After it had been shown effective in suppression of experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), it was evaluated in several clinical studies. In these studies, GA could alter the natural history of MS by both reducing the relapse rate and affecting disability. The clinical therapeutic effect of GA was consistent with the effect on magnetic resonance imaging- defined disease activity and burden in a recent multicenter study. As a daily standard dose, 20 mg of GA is injected subcutaneously. The induction of GA-reactive T-helper 2-like regulatory suppressor cells is thought to be the main mechanism of action. The most common adverse effects are mild injection site reactions. A remarkable but rare adverse effect is the only transient immediate post-injection systemic reaction manifested by flushing, chest tightness, palpitations, and dyspnea. Antibodies to GA which are induced during GA treatment do not interfere with its clinical effects.

Details

einblenden:
ausblenden:
Sprache(n): deu - German
 Datum: 2002-04
 Publikationsstatus: Erschienen
 Seiten: -
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: eDoc: 10804
ISI: 000175496900002
DOI: 10.1007/s00115-001-1257-0
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Nervenarzt
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Berlin : Springer-Verlag
Seiten: - Band / Heft: 73 (4) Artikelnummer: - Start- / Endseite: 321 - 331 Identifikator: ISSN: 0028-2804
CoNE: https://pure.mpg.de/cone/journals/resource/954925427247